Caskey put forth a number of suggestions for overcoming the impediments to new drug discovery and development:

  • Academic initiatives

    • The academic research community needs to increase investments in technology that can improve target validation and drug safety.

  • Government initiatives

    • Government research funding aimed at addressing health challenges needs to be more focused on forecast morbidity and the cost of care in the United States.

    • FDA needs to be adequately funded so it can partner with drug developers and direct the research being performed toward answering important regulatory questions.

  • Private initiatives

    • Small Business Innovation Research and Small Business Technology Transfer regulations need to be revisited and revised to allow for greater investment.

    • New incentives for high-risk investors need to be created, perhaps through tax law.

    • Private disease foundations’ provision of support to the academic community for discovery and to industry for development is beneficial and should be embraced.

    • Experienced investors need to be brought into the innovation process earlier.

    • The pharmaceutical industry and academia need to work together to build a stronger U.S. industry.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement